Replimune Group, Inc.
Regulated industrySells to businessesDevelopment stageTags from an AI model reading the company description.
Key Metrics
- Previous Close
- $13.45
- 52-Week Range
- $1.50 – $16.33
- Market Cap
- $1.23B
- P/E (TTM)
- —
- EPS (TTM)
- -3.15
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- 10.39
- PEG Ratio
- —
- Return on Equity
- -134.29%
- Return on Assets
- -51.30%
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Profit Margin
- 0.00%
- Current Ratio
- 5.23
- Debt/Equity
- 1.06
- Total Debt
- $111.97M
- Free Cash Flow
- $-171.67M
- Revenue Growth
- —
- Earnings Growth
- —
- Enterprise Value
- $1.15B
Market Snapshot
About
Replimune Group is a clinical-stage biotechnology company developing oncolytic immunotherapies for cancer treatment. The company focuses on engineered oncolytic viruses that selectively replicate in tumors to kill cancer cells while stimulating anti-tumor immune responses. Its lead candidate targets multiple solid tumor types.